These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 20020272)

  • 1. Mechanisms of adverse drug reactions to biologics.
    Clarke JB
    Handb Exp Pharmacol; 2010; (196):453-74. PubMed ID: 20020272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse drug reactions to biologics.
    Scherer K; Spoerl D; Bircher AJ
    J Dtsch Dermatol Ges; 2010 Jun; 8(6):411-26. PubMed ID: 20136676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse side-effects to biological agents.
    Pichler WJ
    Allergy; 2006 Aug; 61(8):912-20. PubMed ID: 16867042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management.
    Vultaggio A; Maggi E; Matucci A
    Curr Opin Allergy Clin Immunol; 2011 Jun; 11(3):262-8. PubMed ID: 21460715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy.
    Chung CH
    Oncologist; 2008 Jun; 13(6):725-32. PubMed ID: 18586928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical approaches to dose selection for first-in-human clinical trials with novel biopharmaceuticals.
    Tibbitts J; Cavagnaro JA; Haller CA; Marafino B; Andrews PA; Sullivan JT
    Regul Toxicol Pharmacol; 2010 Nov; 58(2):243-51. PubMed ID: 20558225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management and preparedness for infusion and hypersensitivity reactions.
    Lenz HJ
    Oncologist; 2007 May; 12(5):601-9. PubMed ID: 17522249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hazard identification and risk assessment for biologics targeting the immune system.
    Weir AB
    J Immunotoxicol; 2008 Jan; 5(1):3-10. PubMed ID: 18382852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity/hypersensitivity of biologics.
    Leach MW; Rottman JB; Hock MB; Finco D; Rojko JL; Beyer JC
    Toxicol Pathol; 2014 Jan; 42(1):293-300. PubMed ID: 24240973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions.
    Uetrecht JP
    Drug Metab Rev; 1992; 24(3):299-366. PubMed ID: 1628536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Follow-on biologics: challenges of the "next generation".
    Schellekens H
    Nephrol Dial Transplant; 2005 May; 20 Suppl 4():iv31-36. PubMed ID: 15827057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The danger hypothesis applied to idiosyncratic drug reactions.
    Li J; Uetrecht JP
    Handb Exp Pharmacol; 2010; (196):493-509. PubMed ID: 20020274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
    Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Allergy-immunology. Do we have to be afraid of biological agents?].
    Bart PA
    Rev Med Suisse; 2011 Jan; 7(278):106-7. PubMed ID: 21400939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicities associated with monoclonal antibody infusions in cancer patients.
    Dillman RO; Beauregard JC; Jamieson M; Amox D; Halpern SE
    Mol Biother; 1988; 1(2):81-5. PubMed ID: 3269251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypersensitivity reactions to biological drugs.
    Corominas M; Gastaminza G; Lobera T
    J Investig Allergol Clin Immunol; 2014; 24(4):212-25; quiz 1p following 225. PubMed ID: 25219103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent progress in biomolecular engineering.
    Ryu DD; Nam DH
    Biotechnol Prog; 2000; 16(1):2-16. PubMed ID: 10662483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Appropriate mammalian expression systems for biopharmaceuticals.
    Werner RG; Noé W; Kopp K; Schlüter M
    Arzneimittelforschung; 1998 Aug; 48(8):870-80. PubMed ID: 9748718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.